Cargando…

BRAF V600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis

Langerhans cell histiocytosis (LCH) is a neoplasm of myeloid origin characterized by a clonal proliferation of CD1a(+)/CD207(+) dendritic cells. Recurrent BRAF V600E mutation has been reported in LCH. In the present report, we confirm the feasibility of the high-specificity monoclonal antibody VE1 f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Kaixuan, Wang, Zhe, Ohshima, Koichi, Liu, Yixiong, Zhang, Weichen, Wang, Lu, Fan, Linni, Li, Mingyang, Li, Xia, Wang, Yingmei, Yu, Zhou, Yan, Qingguo, Guo, Shuangping, Wei, Jie, Guo, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006923/ https://www.ncbi.nlm.nih.gov/pubmed/27622040 http://dx.doi.org/10.1080/2162402X.2016.1185582

Ejemplares similares

BRAF V600E-Positive Congenital Multisite Langerhans Cell Histiocytosis
por: Prada Avella, Maria Camila, et al.
Publicado: (2020)

BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay
por: Tatsuno, Michiko, et al.
Publicado: (2016)

BRAF V600E-Positive Multisite Langerhans Cell Histiocytosis in a Preterm Neonate
por: Bates, Sara V., et al.
Publicado: (2013)

Lineage switching of the cellular distribution of BRAF(V600E) in multisystem Langerhans cell histiocytosis
por: Milne, Paul, et al.
Publicado: (2022)

Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis
por: Whitlock, James A., et al.
Publicado: (2023)

Circulating cell-free BRAF V600E during chemotherapy is associated with prognosis of children with Langerhans cell histiocytosis
por: Cui, Lei, et al.
Publicado: (2020)

Langerhans Cell Histiocytosis, Non-Langerhans histiocytosis and concurrent Papillary Thyroid Carcinoma with BRAF V600E mutations: A case report and literature review
por: Wake, Laura, et al.
Publicado: (2019)

Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAF(V600E)-Mutated Langerhans Cell Histiocytosis
por: Yang, Ying, et al.
Publicado: (2021)

Association between clinicopathologic characteristics and BRAF(V600E) expression in Chinese patients with Langerhans cell histiocytosis
por: Huang, Hui, et al.
Publicado: (2019)

Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma
por: Xu, Tianqi, et al.
Publicado: (2019)

Synchronous and Metachronous Thyroid Cancer in Relation to Langerhans Cell Histiocytosis; Involvement of V600E BRAF-Mutation?
por: Moschovi, Maria, et al.
Publicado: (2015)

Clinicopathological features and BRAF(V600E) mutations in patients with isolated hypothalamic-pituitary Langerhans cell histiocytosis
por: Huo, Zhen, et al.
Publicado: (2016)

A study of pathological characteristics and BRAF V600E status in Langerhans cell histiocytosis of Vietnamese children
por: Phan, Thu Dang Anh, et al.
Publicado: (2021)

Cellular distribution of mutations and association with disease risk in Langerhans cell histiocytosis without BRAF(V600E)
por: Milne, Paul, et al.
Publicado: (2022)

Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss
por: Li, Xia, et al.
Publicado: (2017)

Autologous hematopoietic stem cell transplantation for efficient treatment of multisystem, high-risk, BRAF V600E-negative Langerhans cell histiocytosis
por: Pan, Yaozhu, et al.
Publicado: (2019)

BRAF V600E and Pten deletion in mice produces a histiocytic disorder with features of Langerhans cell histiocytosis
por: Nelson, David S., et al.
Publicado: (2019)

BRAF V600E-positive cells as molecular markers of bone marrow disease in pediatric Langerhans cell histiocytosis
por: Kudo, Ko, et al.
Publicado: (2022)

Frequency detection of BRAF V600E mutation in a cohort of pediatric langerhans cell histiocytosis patients by next-generation sequencing
por: Feng, Shunqiao, et al.
Publicado: (2021)

Immune Microenvironment in Langerhans Cell Histiocytosis: Potential Prognostic Indicators
por: Feng, Chuchu, et al.
Publicado: (2021)

New somatic BRAF splicing mutation in Langerhans cell histiocytosis
por: Héritier, Sébastien, et al.
Publicado: (2017)

Adult Onset of BRAF(V600E)-Mutated Langerhans Cell Histiocytosis with Cutaneous Involvement Successfully Diagnosed by Immunohistochemical Staining
por: Tono, Hisayuki, et al.
Publicado: (2015)

Genetic homogeneity of adult Langerhans cell histiocytosis lesions: Insights from BRAF(V600E) mutations in adult populations
por: Selway, Joanne Louise, et al.
Publicado: (2017)

Multisystemic Pediatric Langerhans cell histiocytosis: a comprehensive clinico-pathological and BRAF V600E mutation study at autopsy
por: Kapatia, Gargi, et al.
Publicado: (2020)

Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma
por: Xu, Tianqi, et al.
Publicado: (2021)

Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis
por: Gao, Xue-min, et al.
Publicado: (2022)

Tumor invasion depth is a useful pathologic assessment for predicting outcomes in cervical squamous cell carcinoma after neoadjuvant radiotherapy
por: Lv, Yang, et al.
Publicado: (2015)

Expression of RSK4, CD44 and MMP-9 is upregulated and positively correlated in metastatic ccRCC
por: Ma, Jing, et al.
Publicado: (2020)

MET-overexpressing myxofibrosarcoma frequently exhibit polysomy of chromosome 7 but not MET amplification, especially in high-grade cases: clinical and pathological review of 30 myxofibrosarcoma cases
por: Ma, Shirong, et al.
Publicado: (2018)

Langerhans cell histiocytosis
por: Aruna, D. R., et al.
Publicado: (2011)

Langerhans cell histiocytosis
por: Kumar, Manish, et al.
Publicado: (2018)

BRAF Mutation Analysis in Two Cases of Congenital Self-Healing Langerhans Cell Histiocytosis
por: Takayama, Saki, et al.
Publicado: (2022)

Three decades of progress from surgery to medical therapy for isolated neuroaxis BRAF V600E–positive Langerhans cell histiocytosis management: illustrative case
por: Muthiah, Nallammai, et al.
Publicado: (2021)

Improvement in Pituitary Imaging After Targeted Therapy in Three Children with BRAF-Mutated Langerhans Cell Histiocytosis with Pituitary Involvement
por: Yang, Ying, et al.
Publicado: (2020)

A Risk Model Composed of Complete Blood Count, BRAF V600E and MAP2K1 Predicts Inferior Prognosis of Langerhans Cell Histiocytosis in Children
por: Wang, Leyuan, et al.
Publicado: (2022)

Langerhans cell histiocytosis in an adult with hemophagocytic lymphohistiocytosis
por: Wang, Gang, et al.
Publicado: (2022)

Impact of BRAF(V600E) mutation on aggressiveness and outcomes in adult clonal histiocytosis
por: Razanamahery, Jerome, et al.
Publicado: (2023)

MicroRNA-142-5p contributes to Hashimoto’s thyroiditis by targeting CLDN1
por: Zhu, Jin, et al.
Publicado: (2016)

Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis
por: Tóth, Béla, et al.
Publicado: (2020)

Coexisting BRAF-Mutated Langerhans Cell Histiocytosis and Primary Myelofibrosis with Shared JAK2 Mutation
por: Holst, Johanne Marie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_la4e4lu5p87a8ccj4r3qbl78gt